CYTK
HealthcareCytokinetics, Incorporated
$62.06-0.04 (-0.07%)
Prev Close
$62.13
Open
$61.50
High
$63.03
Low
$60.82
Volume
1.35M
Market Cap
$7.56B
P/E
—
Div Yield
—
Over the past 12 months, insider activity at Cytokinetics, Incorporated (CYTK) has been exclusively selling, with 0 insider purchases totaling $0.00 and 75 insider sales totaling $24.74M. The most recent insider transaction was by Callos Andrew (officer: EVP, Chief Commercial Officer), who sold $104.3K worth of shares on Mar 16, 2026. Cytokinetics, Incorporated operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $7.56B.
Buys (12M)
0
$0.00
Sells (12M)
75
$24.74M
Net Activity
Net Seller
$24.74M
Active Insiders
11
last 12 mo
CYTK Price Chart
CYTK Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Mar 16, 2026↗ | Callos Andrew | officer: EVP, Chief Commercial Officer | Sell | 1,709 | $61.03 | $104.3K | 46,149 |
| Mar 10, 2026↗ | Blum Robert I | director, officer: President & CEO | Sell | 7,931 | $60.72 | $481.6K | 391,673 |
| Mar 10, 2026↗ | Callos Andrew | officer: EVP, Chief Commercial Officer | Sell | 2,582 | $60.72 | $156.8K | 47,858 |
| Mar 10, 2026↗ | Malik Fady Ibraham | officer: EVP Research & Development | Sell | 2,907 | $60.72 | $176.5K | 138,629 |
| Mar 5, 2026↗ | Callos Andrew | officer: EVP, Chief Commercial Officer | Sell | 26,000 | $61.87 | $1.61M | 61,440 |
| Mar 2, 2026↗ | Callos Andrew | officer: EVP, Chief Commercial Officer | Sell | 886 | $61.62 | $54.6K | 50,440 |
| Mar 2, 2026↗ | PARSHALL B LYNNE | director | Sell | 5,000 | $61.21 | $306.1K | 17,933 |
| Feb 5, 2026↗ | Callos Andrew | EVP, Chief Commercial Officer | Sell | 15,000 | $61.93 | $929.0K | 0 |
| Feb 2, 2026↗ | Callos Andrew | EVP, Chief Commercial Officer | Sell | 886 | $62.10 | $55.0K | 0 |
| Jan 5, 2026↗ | Callos Andrew | EVP, Chief Commercial Officer | Sell | 15,000 | $60.28 | $904.2K | 0 |
| Jan 2, 2026↗ | Callos Andrew | EVP, Chief Commercial Officer | Sell | 1,798 | $62.62 | $112.6K | 0 |
| Dec 29, 2025↗ | Callos Andrew | EVP, Chief Commercial Officer | Sell | 1,809 | $62.44 | $113.0K | 0 |
| Dec 22, 2025↗ | Blum Robert I | President & CEO | Sell | 33,361 | $67.70 | $2.26M | 0 |
| Dec 22, 2025↗ | Callos Andrew | EVP, Chief Commercial Officer | Sell | 675 | $62.72 | $42.3K | 0 |
| Dec 22, 2025↗ | Lee Sung | EVP, Chief Financial Officer | Sell | 805 | $62.72 | $50.5K | 0 |
| Dec 22, 2025↗ | Malik Fady Ibraham | EVP Research & Development | Sell | 1,016 | $62.72 | $63.7K | 0 |
| Dec 22, 2025↗ | WIERENGA WENDELL | Director | Sell | 20,000 | $66.14 | $1.32M | 0 |
| Dec 16, 2025↗ | Malik Fady Ibraham | EVP Research & Development | Sell | 2,200 | $61.24 | $134.7K | 0 |
| Dec 8, 2025↗ | Callos Andrew | EVP, Chief Commercial Officer | Sell | 1,042 | $65.96 | $68.7K | 0 |
| Dec 5, 2025↗ | Callos Andrew | EVP, Chief Commercial Officer | Sell | 52,486 | $65.95 | $3.46M | 0 |
| Dec 3, 2025↗ | Blum Robert I | President & CEO | Sell | 5,930 | $65.02 | $385.6K | 0 |
| Dec 3, 2025↗ | Callos Andrew | EVP, Chief Commercial Officer | Sell | 1,368 | $65.02 | $88.9K | 0 |
| Dec 3, 2025↗ | Lee Sung | EVP, Chief Financial Officer | Sell | 1,560 | $65.02 | $101.4K | 0 |
| Dec 3, 2025↗ | Malik Fady Ibraham | EVP Research & Development | Sell | 2,058 | $65.02 | $133.8K | 0 |
| Dec 2, 2025↗ | HENDERSON JOHN T | Director | Sell | 8,750 | $63.90 | $559.1K | 0 |
| Dec 2, 2025↗ | Malik Fady Ibraham | EVP Research & Development | Sell | 2,200 | $63.89 | $140.6K | 0 |
| Dec 1, 2025↗ | Harrington Robert Arthur | Director | Sell | 2,150 | $66.80 | $143.6K | 0 |
| Dec 1, 2025↗ | Kaye Edward M. MD | Director | Sell | 28,064 | $66.72 | $1.87M | 0 |
| Nov 19, 2025↗ | PARSHALL B LYNNE | Director | Sell | 5,000 | $64.73 | $323.6K | 0 |
| Nov 18, 2025↗ | Malik Fady Ibraham | EVP Research & Development | Sell | 2,200 | $66.45 | $146.2K | 0 |
| Nov 11, 2025↗ | Kaye Edward M. MD | Director | Sell | 5,175 | $65.08 | $336.8K | 0 |
| Nov 4, 2025↗ | Malik Fady Ibraham | EVP Research & Development | Sell | 2,295 | $59.55 | $136.7K | 0 |
| Oct 30, 2025↗ | Blum Robert I | President & CEO | Sell | 5,000 | $62.86 | $314.3K | 0 |
| Oct 27, 2025↗ | WIERENGA WENDELL | Director | Sell | 4,375 | $58.68 | $256.7K | 0 |
| Oct 21, 2025↗ | Malik Fady Ibraham | EVP Research & Development | Sell | 2,105 | $58.22 | $122.6K | 0 |
| Oct 16, 2025↗ | Blum Robert I | President & CEO | Sell | 5,000 | $60.03 | $300.1K | 0 |
| Oct 7, 2025↗ | Malik Fady Ibraham | EVP Research & Development | Sell | 2,000 | $60.56 | $121.1K | 0 |
| Oct 6, 2025↗ | Kaye Edward M. MD | Director | Sell | 6,757 | $60.00 | $405.4K | 0 |
| Oct 1, 2025↗ | Blum Robert I | President & CEO | Sell | 5,000 | $55.05 | $275.3K | 0 |
| Sep 30, 2025↗ | Kaye Edward M. MD | Director | Sell | 6,695 | $55.08 | $368.8K | 0 |
| Sep 23, 2025↗ | Malik Fady Ibraham | EVP Research & Development | Sell | 2,000 | $49.28 | $98.6K | 0 |
| Sep 15, 2025↗ | Blum Robert I | President & CEO | Sell | 5,000 | $49.77 | $248.8K | 0 |
| Sep 9, 2025↗ | Malik Fady Ibraham | EVP Research & Development | Sell | 2,000 | $51.29 | $102.6K | 0 |
| Sep 2, 2025↗ | Blum Robert I | President & CEO | Sell | 5,000 | $48.76 | $243.8K | 0 |
| Sep 2, 2025↗ | Harrington Robert Arthur | Director | Sell | 2,150 | $48.67 | $104.6K | 0 |
| Sep 2, 2025↗ | Kaye Edward M. MD | Director | Sell | 6,756 | $50.00 | $337.8K | 0 |
| Aug 19, 2025↗ | Malik Fady Ibraham | EVP Research & Development | Sell | 2,000 | $38.31 | $76.6K | 0 |
| Aug 15, 2025↗ | Blum Robert I | President & CEO | Sell | 5,000 | $38.42 | $192.1K | 0 |
| Aug 5, 2025↗ | Malik Fady Ibraham | EVP Research & Development | Sell | 2,000 | $36.34 | $72.7K | 0 |
| Jul 29, 2025↗ | Blum Robert I | President & CEO | Sell | 5,000 | $36.45 | $182.3K | 0 |
Showing 1–50 of 334
1 / 7
...
CYTK Insider Buying Activity
The following table shows recent insider purchases of Cytokinetics, Incorporated (CYTK) stock reported via SEC Form 4 filings.
No insider buying activity found for CYTK in the last 12 months.
CYTK Insider Selling Activity
The following table shows recent insider sales of Cytokinetics, Incorporated (CYTK) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Mar 16, 2026↗ | Callos Andrew | officer: EVP, Chief Commercial Officer | Sell | 1,709 | $61.03 | $104.3K | 46,149 |
| Mar 10, 2026↗ | Blum Robert I | director, officer: President & CEO | Sell | 7,931 | $60.72 | $481.6K | 391,673 |
| Mar 10, 2026↗ | Callos Andrew | officer: EVP, Chief Commercial Officer | Sell | 2,582 | $60.72 | $156.8K | 47,858 |
| Mar 10, 2026↗ | Malik Fady Ibraham | officer: EVP Research & Development | Sell | 2,907 | $60.72 | $176.5K | 138,629 |
| Mar 5, 2026↗ | Callos Andrew | officer: EVP, Chief Commercial Officer | Sell | 26,000 | $61.87 | $1.61M | 61,440 |
| Mar 2, 2026↗ | Callos Andrew | officer: EVP, Chief Commercial Officer | Sell | 886 | $61.62 | $54.6K | 50,440 |
| Mar 2, 2026↗ | PARSHALL B LYNNE | director | Sell | 5,000 | $61.21 | $306.1K | 17,933 |
| Feb 5, 2026↗ | Callos Andrew | EVP, Chief Commercial Officer | Sell | 15,000 | $61.93 | $929.0K | 0 |
| Feb 2, 2026↗ | Callos Andrew | EVP, Chief Commercial Officer | Sell | 886 | $62.10 | $55.0K | 0 |
| Jan 5, 2026↗ | Callos Andrew | EVP, Chief Commercial Officer | Sell | 15,000 | $60.28 | $904.2K | 0 |
| Jan 2, 2026↗ | Callos Andrew | EVP, Chief Commercial Officer | Sell | 1,798 | $62.62 | $112.6K | 0 |
| Dec 29, 2025↗ | Callos Andrew | EVP, Chief Commercial Officer | Sell | 1,809 | $62.44 | $113.0K | 0 |
| Dec 22, 2025↗ | Blum Robert I | President & CEO | Sell | 33,361 | $67.70 | $2.26M | 0 |
| Dec 22, 2025↗ | Callos Andrew | EVP, Chief Commercial Officer | Sell | 675 | $62.72 | $42.3K | 0 |
| Dec 22, 2025↗ | Lee Sung | EVP, Chief Financial Officer | Sell | 805 | $62.72 | $50.5K | 0 |
| Dec 22, 2025↗ | Malik Fady Ibraham | EVP Research & Development | Sell | 1,016 | $62.72 | $63.7K | 0 |
| Dec 22, 2025↗ | WIERENGA WENDELL | Director | Sell | 20,000 | $66.14 | $1.32M | 0 |
| Dec 16, 2025↗ | Malik Fady Ibraham | EVP Research & Development | Sell | 2,200 | $61.24 | $134.7K | 0 |
| Dec 8, 2025↗ | Callos Andrew | EVP, Chief Commercial Officer | Sell | 1,042 | $65.96 | $68.7K | 0 |
| Dec 5, 2025↗ | Callos Andrew | EVP, Chief Commercial Officer | Sell | 52,486 | $65.95 | $3.46M | 0 |
| Dec 3, 2025↗ | Blum Robert I | President & CEO | Sell | 5,930 | $65.02 | $385.6K | 0 |
| Dec 3, 2025↗ | Callos Andrew | EVP, Chief Commercial Officer | Sell | 1,368 | $65.02 | $88.9K | 0 |
| Dec 3, 2025↗ | Lee Sung | EVP, Chief Financial Officer | Sell | 1,560 | $65.02 | $101.4K | 0 |
| Dec 3, 2025↗ | Malik Fady Ibraham | EVP Research & Development | Sell | 2,058 | $65.02 | $133.8K | 0 |
| Dec 2, 2025↗ | HENDERSON JOHN T | Director | Sell | 8,750 | $63.90 | $559.1K | 0 |
| Dec 2, 2025↗ | Malik Fady Ibraham | EVP Research & Development | Sell | 2,200 | $63.89 | $140.6K | 0 |
| Dec 1, 2025↗ | Harrington Robert Arthur | Director | Sell | 2,150 | $66.80 | $143.6K | 0 |
| Dec 1, 2025↗ | Kaye Edward M. MD | Director | Sell | 28,064 | $66.72 | $1.87M | 0 |
| Nov 19, 2025↗ | PARSHALL B LYNNE | Director | Sell | 5,000 | $64.73 | $323.6K | 0 |
| Nov 18, 2025↗ | Malik Fady Ibraham | EVP Research & Development | Sell | 2,200 | $66.45 | $146.2K | 0 |
| Nov 11, 2025↗ | Kaye Edward M. MD | Director | Sell | 5,175 | $65.08 | $336.8K | 0 |
| Nov 4, 2025↗ | Malik Fady Ibraham | EVP Research & Development | Sell | 2,295 | $59.55 | $136.7K | 0 |
| Oct 30, 2025↗ | Blum Robert I | President & CEO | Sell | 5,000 | $62.86 | $314.3K | 0 |
| Oct 27, 2025↗ | WIERENGA WENDELL | Director | Sell | 4,375 | $58.68 | $256.7K | 0 |
| Oct 21, 2025↗ | Malik Fady Ibraham | EVP Research & Development | Sell | 2,105 | $58.22 | $122.6K | 0 |
| Oct 16, 2025↗ | Blum Robert I | President & CEO | Sell | 5,000 | $60.03 | $300.1K | 0 |
| Oct 7, 2025↗ | Malik Fady Ibraham | EVP Research & Development | Sell | 2,000 | $60.56 | $121.1K | 0 |
| Oct 6, 2025↗ | Kaye Edward M. MD | Director | Sell | 6,757 | $60.00 | $405.4K | 0 |
| Oct 1, 2025↗ | Blum Robert I | President & CEO | Sell | 5,000 | $55.05 | $275.3K | 0 |
| Sep 30, 2025↗ | Kaye Edward M. MD | Director | Sell | 6,695 | $55.08 | $368.8K | 0 |
| Sep 23, 2025↗ | Malik Fady Ibraham | EVP Research & Development | Sell | 2,000 | $49.28 | $98.6K | 0 |
| Sep 15, 2025↗ | Blum Robert I | President & CEO | Sell | 5,000 | $49.77 | $248.8K | 0 |
| Sep 9, 2025↗ | Malik Fady Ibraham | EVP Research & Development | Sell | 2,000 | $51.29 | $102.6K | 0 |
| Sep 2, 2025↗ | Blum Robert I | President & CEO | Sell | 5,000 | $48.76 | $243.8K | 0 |
| Sep 2, 2025↗ | Harrington Robert Arthur | Director | Sell | 2,150 | $48.67 | $104.6K | 0 |
| Sep 2, 2025↗ | Kaye Edward M. MD | Director | Sell | 6,756 | $50.00 | $337.8K | 0 |
| Aug 19, 2025↗ | Malik Fady Ibraham | EVP Research & Development | Sell | 2,000 | $38.31 | $76.6K | 0 |
| Aug 15, 2025↗ | Blum Robert I | President & CEO | Sell | 5,000 | $38.42 | $192.1K | 0 |
| Aug 5, 2025↗ | Malik Fady Ibraham | EVP Research & Development | Sell | 2,000 | $36.34 | $72.7K | 0 |
| Jul 29, 2025↗ | Blum Robert I | President & CEO | Sell | 5,000 | $36.45 | $182.3K | 0 |
CYTK Insiders
Similar Stocks to CYTK
VRTX
Vertex Pharmaceuticals Incorporated
$452.29-2.20%
$121.44B
REGN
Regeneron Pharmaceuticals, Inc.
$745.34-1.66%
$77.57B
ALNY
Alnylam Pharmaceuticals, Inc.
$317.24-0.96%
$42.07B
INSM
Insmed Incorporated
$143.85-0.06%
$30.07B
UTHR
United Therapeutics Corporation
$531.23-1.63%
$23.50B
MRNA
Moderna, Inc.
$52.27-3.15%
$20.76B
ROIV
Roivant Sciences Ltd.
$27.86-1.55%
$20.08B
RPRX
Royalty Pharma plc
$45.94-0.36%
$19.56B